Glaxo India Ltd has posted a net profit of Rs 102 m (down 28%) for the quarter ended March 31, 2001. Net sales grew by 6.1% to Rs 1,944 m compared to Rs 1,832 m in the corresponding period last fiscal. Operating margins showed a significant improvement, increasing by more than 60 basis points. The dip in net profits was primarily due to comparatively lower other income. Other Income for the corresponding previous period last year included a income Rs 50 m from sale of brands. Barring Other Income, Profit Before Tax has in effect increased by more than 22.9%
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Diluted Earnings per share*
P/E (at current price)
The company has also received approval of the shareholders to merge Smithkline Beecham Pharma with effect from 12th April 2001.
In a related development the company recently decided to expand the business activities of its animal health division by entering new areas like antibiotic and ectoparasite and nutrition segments, launching technically superior products in cattle and poultry segment besides launching line extension of existing products.The animal healthmarket in the country is estimated to be around Rs 8 bn with the poultry sector alone contributing 45%.
At the current market price of Rs 386, the stock is trading at 57 times its annualised 1QFY02 earnings.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407